Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...
New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies, and can guide treatment decisions for patients with Lynch-associated cancers LEIDEN, Netherlands & ...
A novel xenonucleic acid mediated molecular clamping technology for early colorectal cancer diagnostics. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not ...
MSI by NGS allowed for simultaneous screening for LS and categorization of EC into molecular subtypes with prognostic and therapeutic implications. NGS readily identified the four EC molecular ...
Please provide your email address to receive an email when new articles are posted on . Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced ...
Roche announced US Food and Drug Administration (FDA) approval of the Ventana MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to ...
Dr Philippe Taniere – Understanding biomarker testing for immunotherapy; PD-L1 (Programmed Death-Ligand 1) expression, Mismatch Repair (MMR) testing and the importance of Microsatellite Instability ...
In today’s era of precision medicine, the management of most solid tumors is increasingly driven by biomarker testing, the results of which often drive treatment decisions. Perhaps the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results